Loading...
Loading...
UNCY| Name | Value |
|---|---|
| Revenues | 0.7M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.6M |
| Operating Expense | 4.9M |
| Operating I/L | -4.2M |
| Other Income/Expense | -10.4M |
| Interest Income | 0.0M |
| Pretax | -14.6M |
| Income Tax Expense | 10.6M |
| Net Income/Loss | -25.2M |
Unicycive Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for kidney diseases. The company's primary revenue stream comes from the development and commercialization of Renazorb, a treatment for hyperphosphatemia in chronic kidney disease patients, and UNI 494, designed for acute kidney injury treatment.
